<VariationArchive VariationID="209105" VariationName="NM_007294.4(BRCA1):c.594_597delTGTG" VariationType="Deletion" Accession="VCV000209105" Version="13" RecordType="classified" NumberOfSubmissions="6" NumberOfSubmitters="4" DateLastUpdated="2024-07-29" DateCreated="2015-09-29" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="205705" VariationID="209105">
      <GeneList>
        <Gene Symbol="BRCA1" FullName="BRCA1 DNA repair associated" GeneID="672" HGNC_ID="HGNC:1100" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q21.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="43044295" stop="43170327" display_start="43044295" display_stop="43170327" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="41196311" stop="41277499" display_start="41196311" display_stop="41277499" Strand="-" />
          </Location>
          <OMIM>113705</OMIM>
          <Haploinsufficiency last_evaluated="2021-09-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-09-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_007294.4(BRCA1):c.594_597delTGTG</Name>
      <CanonicalSPDI>NC_000017.11:43095918:CACAC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17q21.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="43095919" stop="43095922" display_start="43095919" display_stop="43095922" variantLength="4" positionVCF="43095918" referenceAlleleVCF="CCACA" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="41247936" stop="41247939" display_start="41247936" display_stop="41247939" variantLength="4" positionVCF="41247935" referenceAlleleVCF="CCACA" alternateAlleleVCF="C" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_007294.4" sequenceAccession="NM_007294" sequenceVersion="4" change="c.594_597delTGTG" MANESelect="true">
            <Expression>NM_007294.4:c.594_597delTGTG</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001574" Type="splice acceptor variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.41247937_41247940del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.41247937_41247940del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.43095920_43095923del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.43095920_43095923del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_005905.2" sequenceAccession="NG_005905" sequenceVersion="2" change="g.122062_122065del">
            <Expression>NG_005905.2:g.122062_122065del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_292" sequenceAccession="LRG_292">
            <Expression>LRG_292:g.122062_122065del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_292t1" sequenceAccession="LRG_292t1">
            <Expression>LRG_292t1:c.594_597del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA276117" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="113705.0041" DB="OMIM" />
        <XRef Type="rs" ID="797045175" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_007294.4(BRCA1):c.594_597delTGTG AND Fanconi anemia complementation group A" Accession="RCV000191042" Version="9">
        <ClassifiedConditionList TraitSetID="883">
          <ClassifiedCondition DB="MedGen" ID="C3469521">Fanconi anemia complementation group A</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2015-05-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_007294.4(BRCA1):c.594_597delTGTG AND Breast-ovarian cancer, familial, susceptibility to, 1" Accession="RCV000258289" Version="14">
        <ClassifiedConditionList TraitSetID="1917">
          <ClassifiedCondition DB="MedGen" ID="C2676676">Breast-ovarian cancer, familial, susceptibility to, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2015-10-02" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_007294.4(BRCA1):c.594_597delTGTG AND Fanconi anemia, complementation group S" Accession="RCV000585825" Version="13">
        <ClassifiedConditionList TraitSetID="40619">
          <ClassifiedCondition DB="MedGen" ID="C4554406">Fanconi anemia, complementation group S</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2015-02-01" SubmissionCount="2">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_007294.4(BRCA1):c.594_597delTGTG AND Hereditary cancer-predisposing syndrome" Accession="RCV001024704" Version="11">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-03-07" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-03-07" NumberOfSubmissions="6" NumberOfSubmitters="4" DateCreated="2015-09-29" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">24569164</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25472942</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33098347</ID>
        </Citation>
        <DescriptionHistory Dated="2020-03-16">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="40619" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="38588" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia, complementation group S</ElementValue>
                <XRef ID="MONDO:0054748" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FANCS</ElementValue>
                <XRef Type="MIM" ID="617883" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16264" />
                <XRef ID="16264" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <XRef ID="C4554406" DB="MedGen" />
              <XRef ID="MONDO:0054748" DB="MONDO" />
              <XRef Type="MIM" ID="617883" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="883" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="9887" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Fanconi anemia, group A</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group A</ElementValue>
                <XRef ID="MONDO:0009215" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCA</ElementValue>
                <XRef Type="MIM" ID="227650" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">FANCA-Related Fanconi Anemia</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15170" />
                <XRef ID="15170" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3469521" DB="MedGen" />
              <XRef ID="MONDO:0009215" DB="MONDO" />
              <XRef Type="MIM" ID="227650" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1917" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4711" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 1</ElementValue>
                <XRef ID="MONDO:0011450" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 1</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+1/7865" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">OVARIAN CANCER, SUSCEPTIBILITY TO</ElementValue>
                <XRef Type="Allelic variant" ID="602667.0001" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA1</ElementValue>
                <XRef Type="MIM" ID="604370" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12351" />
                <XRef ID="12351" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021517" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501743" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514601" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017876" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501746" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509982" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512320" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522161" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501817" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325409" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, 2024</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2676676" DB="MedGen" />
              <XRef ID="MONDO:0011450" DB="MONDO" />
              <XRef Type="MIM" ID="604370" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="455591" SubmissionDate="2015-09-11" DateLastUpdated="2015-09-29" DateCreated="2015-09-29">
        <ClinVarSubmissionID localKey="NM_007294.3:c.594_597delTGTG|OMIM:227650" />
        <ClinVarAccession Accession="SCV000246116" DateUpdated="2015-09-29" DateCreated="2015-09-29" Type="SCV" Version="1" SubmitterName="University of Washington Center for Mendelian Genomics, University of Washington" OrgID="505516" OrganizationCategory="laboratory" OrgAbbreviation="UW-CMG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-05-19">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25472942</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>maternal</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="VariantChromosomes" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_007294.3:Exon9</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_007294.3:c.594_597delTGTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Fanconi anemia, complementation group A</ElementValue>
            </Name>
            <XRef DB="OMIM" ID="227650" Type="MIM" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3465236" SubmissionDate="2021-07-20" DateLastUpdated="2021-07-30" DateCreated="2021-07-30">
        <ClinVarSubmissionID localKey="NM_007294.4:c.594_597delTGTG|OMIM:617883" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001761914" DateUpdated="2021-07-30" DateCreated="2021-07-30" Type="SCV" Version="1" SubmitterName="University of Washington Center for Mendelian Genomics, University of Washington" OrgID="505516" OrganizationCategory="laboratory" OrgAbbreviation="UW-CMG" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Citation>
              <ID Source="PubMed">33098347</ID>
            </Citation>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_007294.4:c.594_597delTGTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617883" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10048477</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="625473" SubmissionDate="2016-10-28" DateLastUpdated="2022-12-11" DateCreated="2016-11-06">
        <ClinVarSubmissionID localKey="NM_007294.3:c.594_597del|OMIM:604370" submittedAssembly="hg18" />
        <ClinVarAccession Accession="SCV000326365" DateUpdated="2022-12-11" DateCreated="2016-11-06" Type="SCV" Version="4" SubmitterName="Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge" OrgID="505954" OrganizationCategory="consortium" OrgAbbreviation="CIMBA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CIMBA Mutation Classification guidelines May 2016</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/nhgqiuyb/cimba_mutation_classification_guidelines_may16.pdf</URL>
            <CitationText>CIMBA_Mutation_Classification_guidelines_May16.pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_007294.3:c.594_597del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604370" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>CIMBA_20161005</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1359892" SubmissionDate="2021-10-06" DateLastUpdated="2022-12-31" DateCreated="2018-03-14">
        <ClinVarSubmissionID localKey="113705.0041_FANCONI ANEMIA, COMPLEMENTATION GROUP S" title="BRCA1, 4-BP DEL, NT594_FANCONI ANEMIA, COMPLEMENTATION GROUP S" />
        <ClinVarAccession Accession="SCV000693741" DateUpdated="2022-12-31" DateCreated="2018-03-14" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-02-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">For discussion of the 4-bp deletion (c.594_597del4, NM_007294) in the BRCA1 gene, predicted to result in a frameshift and premature termination (Ser198ArgfsTer35), that was found in compound heterozygous state in a patient with Fanconi anemia complementation group S (FANCS; 617883) by Sawyer et al. (2014), see 113705.0040. Heterozygous carriers of this mutation had increased susceptibility to breast-ovarian cancer (BROVCA1; 604370).</Attribute>
              <Citation>
                <ID Source="PubMed">25472942</ID>
              </Citation>
              <XRef DB="OMIM" ID="617883" Type="MIM" />
              <XRef DB="OMIM" ID="604370" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA1" />
          </GeneList>
          <Name>BRCA1, 4-BP DEL, NT594</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, NT594</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="113705.0041" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">FANCONI ANEMIA, COMPLEMENTATION GROUP S</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1359893" SubmissionDate="2021-10-06" DateLastUpdated="2022-12-31" DateCreated="2016-11-06">
        <ClinVarSubmissionID localKey="113705.0041_BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1" title="BRCA1, 4-BP DEL, NT594_BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1" />
        <ClinVarAccession Accession="SCV000693742" DateUpdated="2022-12-31" DateCreated="2016-11-06" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-02-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to included disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">For discussion of the 4-bp deletion (c.594_597del4, NM_007294) in the BRCA1 gene, predicted to result in a frameshift and premature termination (Ser198ArgfsTer35), that was found in compound heterozygous state in a patient with Fanconi anemia complementation group S (FANCS; 617883) by Sawyer et al. (2014), see 113705.0040. Heterozygous carriers of this mutation had increased susceptibility to breast-ovarian cancer (BROVCA1; 604370).</Attribute>
              <Citation>
                <ID Source="PubMed">25472942</ID>
              </Citation>
              <XRef DB="OMIM" ID="617883" Type="MIM" />
              <XRef DB="OMIM" ID="604370" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA1" />
          </GeneList>
          <Name>BRCA1, 4-BP DEL, NT594</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, NT594</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="113705.0041" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="included">BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2326762" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2020-03-16">
        <ClinVarSubmissionID localKey="a453089|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001186772" DateUpdated="2024-05-01" DateCreated="2020-03-16" Type="SCV" Version="4" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-03-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24569164</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25472942</ID>
          </Citation>
          <Comment>The c.594_597delTGTG variant, located in coding exon 8 of the BRCA1 gene, results from a deletion of 4 nucleotides at nucleotide positions 594 to 597, causing a translational frameshift with a predicted alternate stop codon (p.S198Rfs*35). This alteration was identified in a compound heterozygous state with another pathogenic BRCA1 alteration in a patient with features that were consistent with Fanconi Anemia including increased chromosome breakage upon DNA damage. Cells from this patient had numerous defects including reduced BRCA1 and RAD51 foci formation and ultrasensitivity to PARP inhibitors. These defects were rescued by a partial BRCA1 transgene to a level comparable to a sibling whose cells had only one BRCA1 alteration. This suggests that these defects are due specifically to BRCA1 deficiency (Sawyer SL et al. Cancer Discov, 2015 Feb;5:135-42). Alterations that result in premature protein truncation are typically deleterious in nature; however, this alteration occurs in one of the exons that is absent in a predominant, in-frame, naturally occurring isoform (&amp;Delta;7_8, also known as &amp;Delta;9,10 in the literature) and is likely to be spliced out in this normal isoform that produces a partially functional protein (Colombo M et al. Hum. Mol. Genet. 2014 Jul;23:3666-80; Whiley PJ et al. Clin. Chem. 2014 Feb;60:341-52), Therefore, the effect of this variant in a heterozygous state may be hypomorphic. Based on the majority of available evidence to date, this variant is likely to be pathogenic. However, because this variant is identified in one or more patients with Fanconi Anemia it may be hypomorphic and thus, carriers of this variant and their families may present with reduced risks, and not with the typical clinical characteristics of a high-risk pathogenic BRCA1 alteration. As risk estimates are unknown at this time, clinical correlation is advised.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_007294.3:c.594_597delTGTG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>CancerPanelNovelsThrough2019Q4</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1359892" TraitType="Disease" MappingType="Name" MappingValue="FANCONI ANEMIA, COMPLEMENTATION GROUP S" MappingRef="Preferred">
        <MedGen CUI="C4554406" Name="Fanconi anemia, complementation group S" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="455591" TraitType="Disease" MappingType="Name" MappingValue="Fanconi anemia, complementation group A" MappingRef="Preferred">
        <MedGen CUI="C3469521" Name="Fanconi anemia complementation group A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1359893" TraitType="Disease" MappingType="Name" MappingValue="BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1" MappingRef="Alternate">
        <MedGen CUI="C2676676" Name="Breast-ovarian cancer, familial, susceptibility to, 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2326762" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="625473" TraitType="Disease" MappingType="XRef" MappingValue="604370" MappingRef="OMIM">
        <MedGen CUI="C2676676" Name="Breast-ovarian cancer, familial, susceptibility to, 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3465236" TraitType="Disease" MappingType="XRef" MappingValue="617883" MappingRef="OMIM">
        <MedGen CUI="C4554406" Name="Fanconi anemia, complementation group S" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2021-11-13">SCV001879078</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

